Diligence memo · auto-generated · as of July 2, 2026

Transenterix Inc.

Transenterix Inc. looks under-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Transenterix Inc. operates in Other Health Care, based in MORRISVILLE.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Transenterix Inc. has raised $210M in disclosed capital across 8 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).

Largest single filing: $160M on 2013-09-03.

Most recent recorded round closed around 2017-09-12.

Valuation (modeled)modeled

Provath models Transenterix Inc. at approximately $22M (range $5.1M–$48M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.01× the median modeled value of Series D+ Other Health Care companies in 2016–2018 (7 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 13 months.

Last raise 8.8 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round stepped up 8.2× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 98% of Other Health Care peers (5377 compared).

Modeled value ranks above 50% of those peers.

Closest niche peers: BNVC Group Holdings, Inc., Endologix Inc /De/, SYFS Intermediate Holdings, LLC, Allied Integral United, Inc., OneOncology Parent Holdings, LLC.

Peoplefiled

24 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.